glp 1 compounders Novo asks FDA to prevent from making GLP-1 knockoffs GLP-1 Drugs: Ohio Board of

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)

In doing so, oral formulations could support the normalisation of obesity management making initiation simpler for general practitioners and reducing the stigma that continues to limit the uptake of injectable therapies

Youll also find tips for staying consistent and managing your routine, along with guidance on when adjustments may be necessary

Thank you Vitastir

Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up